Shi, R., Lu, T., Ku, G., Ding, H., Saito, T., Gibiansky, L., . . . Lu, D. (2020). Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol.
Chicago Style CitationShi, Rong, et al. "Asian Race and Origin Have No Clinically Meaningful Effects On Polatuzumab Vedotin Pharmacokinetics in Patients With Relapsed/refractory B-cell Non-Hodgkin Lymphoma." Cancer Chemother Pharmacol 2020.
Cita MLAShi, Rong, et al. "Asian Race and Origin Have No Clinically Meaningful Effects On Polatuzumab Vedotin Pharmacokinetics in Patients With Relapsed/refractory B-cell Non-Hodgkin Lymphoma." Cancer Chemother Pharmacol 2020.